Roadmap 2018

Discussion in 'AstraZeneca' started by anonymous, Jan 5, 2018 at 12:26 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Well for all the “HQ insider” posts and whatnot...2018 is here.

    Where is the road leading or ending?
     

  2. anonymous

    anonymous Guest

    AZ is a one way highway to obscurity. Leadership designs a few tangent bypasses that always end up at the same destination, failure, layoffs, reorgs, and false promises. There hasn't been a future for any real career opportunities for over 10 years. Don't be fooled by the shining object and focus on the long term reality.
    The Pharma sales model is dead but leadership in many companies continue to push the reach and frequency model that we all know is total bullshit. They need us to justify their jobs.
     
  3. anonymous

    anonymous Guest

    More like Detour 2018
     
  4. anonymous

    anonymous Guest

    Wall Street is being played for fools. At some point in time they will grow tired of the charade and will begin shorting the piss and shit out of AZN. Until then keep collecting that AZ corporate welfare check. Big hit coming to the CVMD portfolio in 2018. Displacement will proceed.
     
  5. anonymous

    anonymous Guest

    Corporate welfare pays a lot more than the welfare you're on angry clown.
     
  6. anonymous

    anonymous Guest

    Hey, a little hint: more resources are being poured into cvmd than any other division. There's not a safer spot to be. Just ask your respiratory , pc counterparts. Who has the spending budgets?
    CVMD is the spot to be in.
     
  7. anonymous

    anonymous Guest

    The spot to be in is a good analogy. You know that stubborn brown stain in your underwear that just won't come completely clean? CVMD looks and smells a lot like that spot.
     
  8. anonymous

    anonymous Guest

    CVMD has spending budgets? That is laughable. Only one brand in their portfolio is pissing away money, bad after worse. The ROI has not come and will never come. TA of the year will have just enough time to ride out their accolades before they are exposed as frauds. Looking forward to the excuses made and the adjustments made MULTIPLE TIMES to their 2018 budgets.
     
  9. anonymous

    anonymous Guest

    A US-based company will take their repatriated lower-taxed money and buy AZN.
     
  10. anonymous

    anonymous Guest

    CVMD is akin to Yale educated reps, other divisions akin to that junior college just down the street.
    We are keeping AZ afloat.
     
  11. anonymous

    anonymous Guest

    Keep telling yourself that Mr CBD.
     
  12. anonymous

    anonymous Guest

    This really made me laugh. I am sure that if you asked any M.D. or C.D. what they think of pharma reps that they would be gushing with praise on how qualified and brilliant they are. That is why they stand in line just to spend 10 minutes of their valuable time with one of our representatives. Fucking idiot.
     
  13. anonymous

    anonymous Guest

    can you share some of the stuff u are taking? it must be some good shit.
     
  14. anonymous

    anonymous Guest

    Pfizer
     
  15. anonymous

    anonymous Guest

    That ship sailed. Pfizer has a portfolio directly competing with AZ. Too many assets would need to be divested. Speaking of ships sinking.